Literature DB >> 22777088

Risk of perinatal death in early-onset intrauterine growth restriction according to gestational age and cardiovascular Doppler indices: a multicenter study.

Mónica Cruz-Lemini1, Fàtima Crispi, Tim Van Mieghem, Daniel Pedraza, Rogelio Cruz-Martínez, Ruthy Acosta-Rojas, Francesc Figueras, Mauro Parra-Cordero, Jan Deprest, Eduard Gratacós.   

Abstract

OBJECTIVE: To assess the value of gestational age and cardiovascular Doppler indices in predicting perinatal mortality in a multicenter cohort of early-onset intrauterine growth-restricted (IUGR) fetuses.
METHODS: A multicenter prospective cohort study including 157 early-onset (<34 weeks) IUGR cases with abnormal umbilical artery (UA) Doppler was conducted. Cardiovascular assessment included the ductus venosus (DV), the aortic isthmus flow index (IFI), and the myocardial performance index (MPI). Isolated and combined values to predict the risk of perinatal death were evaluated by logistic regression and by decision tree analysis, where the gestational age at delivery, UA, and middle cerebral artery (MCA) were also included as covariates.
RESULTS: Perinatal mortality was 17% (27/157). All parameters were significantly associated with perinatal death, with individual odds ratios (OR) of 25.2 for gestational age below 28 weeks, 12.1 for absent/reversed DV atrial flow, 5.3 for MCA pulsatility index <5th centile, 4.6 for UA absent/reversed diastolic end-flow, 1.8 for IFI <5th centile, and 1.6 for MPI >95th centile. Decision tree analysis identified gestational age at birth as the best predictor of death (<26 weeks, 93% mortality; 26-28 weeks, 29% mortality, and >28 weeks, 3% mortality). Between 26 and 28 weeks, DV atrial flow allowed further stratification between high (60%) and low risk (18%) of mortality.
CONCLUSIONS: Gestational age largely determines the risk of perinatal mortality in early-onset IUGR before 26 weeks and later than 28 weeks of gestation. The DV may improve clinical management by stratifying the probability of death between 26 and 28 weeks of gestation.
Copyright © 2012 S. Karger AG, Basel.

Entities:  

Mesh:

Year:  2012        PMID: 22777088     DOI: 10.1159/000333001

Source DB:  PubMed          Journal:  Fetal Diagn Ther        ISSN: 1015-3837            Impact factor:   2.587


  16 in total

1.  Intermediate Diastolic Velocity as a Parameter of Cardiac Dysfunction in Growth-Restricted Fetuses.

Authors:  Xiangna Tang; Edgar Hernandez-Andrade; Hyunyoung Ahn; Maynor Garcia; Homam Saker; Steven J Korzeniewski; Adi L Tarca; Lami Yeo; Sonia S Hassan; Roberto Romero
Journal:  Fetal Diagn Ther       Date:  2015-08-12       Impact factor: 2.587

2.  FIGO (international Federation of Gynecology and obstetrics) initiative on fetal growth: best practice advice for screening, diagnosis, and management of fetal growth restriction.

Authors:  Nir Melamed; Ahmet Baschat; Yoav Yinon; Apostolos Athanasiadis; Federico Mecacci; Francesc Figueras; Vincenzo Berghella; Amala Nazareth; Muna Tahlak; H David McIntyre; Fabrício Da Silva Costa; Anne B Kihara; Eran Hadar; Fionnuala McAuliffe; Mark Hanson; Ronald C Ma; Rachel Gooden; Eyal Sheiner; Anil Kapur; Hema Divakar; Diogo Ayres-de-Campos; Liran Hiersch; Liona C Poon; John Kingdom; Roberto Romero; Moshe Hod
Journal:  Int J Gynaecol Obstet       Date:  2021-03       Impact factor: 3.561

3.  A Low Cerebroplacental Ratio at 20-24 Weeks of Gestation Can Predict Reduced Fetal Size Later in Pregnancy or at Birth.

Authors:  Edgar Hernandez-Andrade; Eli Maymon; Offer Erez; Homam Saker; Suchaya Luewan; Maynor Garcia; Hyunyoung Ahn; Adi L Tarca; Bogdan Done; Steven J Korzeniewski; Sonia S Hassan; Roberto Romero
Journal:  Fetal Diagn Ther       Date:  2017-09-20       Impact factor: 2.587

Review 4.  Detection and assessment of brain injury in the growth-restricted fetus and neonate.

Authors:  Atul Malhotra; Michael Ditchfield; Michael C Fahey; Margie Castillo-Melendez; Beth J Allison; Graeme R Polglase; Euan M Wallace; Ryan Hodges; Graham Jenkin; Suzanne L Miller
Journal:  Pediatr Res       Date:  2017-05-17       Impact factor: 3.756

5.  Fetal cardiac function: Feasibility in obtaining the right modified myocardial performance index in a single Doppler waveform.

Authors:  Neama Meriki; Alec W Welsh
Journal:  Australas J Ultrasound Med       Date:  2017-02-01

6.  Quantitative longitudinal T2* mapping for assessing placental function and association with adverse pregnancy outcomes across gestation.

Authors:  Matthias C Schabel; Victoria H J Roberts; Karen J Gibbins; Monica Rincon; Jessica E Gaffney; Aaron D Streblow; Adam M Wright; Jamie O Lo; Byung Park; Christopher D Kroenke; Kathryn Szczotka; Nathan R Blue; Jessica M Page; Kathy Harvey; Michael W Varner; Robert M Silver; Antonio E Frias
Journal:  PLoS One       Date:  2022-07-19       Impact factor: 3.752

7.  In Vivo Detection of Perinatal Brain Metabolite Changes in a Rabbit Model of Intrauterine Growth Restriction (IUGR).

Authors:  Rui V Simões; Emma Muñoz-Moreno; Rodrigo J Carbajo; Anna González-Tendero; Miriam Illa; Magdalena Sanz-Cortés; Antonio Pineda-Lucena; Eduard Gratacós
Journal:  PLoS One       Date:  2015-07-24       Impact factor: 3.240

8.  Metabolomic profile of umbilical cord blood plasma from early and late intrauterine growth restricted (IUGR) neonates with and without signs of brain vasodilation.

Authors:  Magdalena Sanz-Cortés; Rodrigo J Carbajo; Fatima Crispi; Francesc Figueras; Antonio Pineda-Lucena; Eduard Gratacós
Journal:  PLoS One       Date:  2013-12-02       Impact factor: 3.240

9.  Metabolomics reveals metabolic alterations by intrauterine growth restriction in the fetal rabbit brain.

Authors:  Erwin van Vliet; Elisenda Eixarch; Miriam Illa; Ariadna Arbat-Plana; Anna González-Tendero; Helena T Hogberg; Liang Zhao; Thomas Hartung; Eduard Gratacos
Journal:  PLoS One       Date:  2013-05-27       Impact factor: 3.240

10.  Paternal metabolic and cardiovascular risk factors for fetal growth restriction: a case-control study.

Authors:  Sara Hillman; Donald M Peebles; David J Williams
Journal:  Diabetes Care       Date:  2013-01-11       Impact factor: 19.112

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.